Stock FUSN FUSN PHAR
Add to a list
To use this feature you must be a member
Log inSign up

News FUSN PHAR

Equities

FUSN

CA36118A1003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
21.48 USD +0.47% Intraday chart for FUSN PHAR +0.14% +123.52%
May. 09 Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer CI
May. 07 Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
PR
Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
CI
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
BU
Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
AQ
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
PR
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
AQ
TD Cowen Downgrades Fusion Pharmaceuticals to Hold
MT
Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265
CI
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
AQ
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN
PR
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca
MT
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
AQ
B. Riley Downgrades Fusion Pharmaceuticals to Neutral From Buy on Heels of Announced Sale to AstraZeneca, Adjusts PT to $23 From $13
MT
Bloom Burton Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21.50 From $20
MT
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16
MT
JonesTrading Downgrades Fusion Pharmaceuticals to Hold From Buy
MT
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FUSN Stock
  4. News FUSN PHAR
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW